Profile data is unavailable for this security.
About the company
WAKAMOTO PHARMACEUTICAL CO., LTD. is a Japan-based company mainly engaged in the manufacture and sale of ethical drugs such as gastrointestinal drugs and non-prescription drugs. The Company operates through four business segments. The Pharmaceuticals segment is involved in the manufacture and sale of innovator drugs, generic drugs and optiaid series supplements mainly in the ophthalmic field, as well as the commission of production and the sale of diagnostic drugs and raw materials in Japan. The Healthcare segment sales its core product Kawakami Wakamoto, the Avantbise series of medicated toothpastes that promote bad breath prevention based on evidence and Avantbise Oral Tablet mainly in the mail order business. The International segment is involved in the business related to the export of products and raw materials mainly in Asia and Europe, as well as the new license in and out business. The Real Estate Leasing segment is involved in the rental business of Coredo Muromachi.
- Revenue in JPY (TTM)7.98bn
- Net income in JPY-177.67m
- Incorporated1933
- Employees292.00
- LocationWakamoto Pharmaceutical Co Ltd2-2-2, Nihombashihon-choCHUO-KU 103-8330JapanJPN
- Phone+81 332790371
- Fax+81 332796450
- Websitehttps://www.wakamoto-pharm.co.jp/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Delta-Fly Pharma Inc | 0.00 | -1.26bn | 6.08bn | 11.00 | -- | 3.60 | -- | -- | -187.93 | -187.93 | 0.00 | 205.25 | 0.00 | -- | -- | 0.00 | -92.45 | -53.35 | -103.56 | -55.60 | -- | -- | -- | -769.75 | -- | -391.17 | 0.00 | -- | -100.00 | -- | -37.37 | -- | -- | -- |
| CellSeed Inc | 190.13m | -846.53m | 6.72bn | 35.00 | -- | 3.05 | -- | 35.34 | -29.28 | -29.28 | 6.61 | 68.81 | 0.0948 | 1.62 | 4.90 | 5,432,400.00 | -42.22 | -49.69 | -45.69 | -54.55 | 56.36 | 63.66 | -445.23 | -428.62 | 18.66 | -601.01 | 0.0653 | -- | 50.39 | -28.62 | -11.43 | -- | 80.73 | -- |
| Noile-Immune Biotech Inc | 316.82m | -1.13bn | 6.84bn | 28.00 | -- | 1.20 | -- | 21.59 | -26.14 | -26.14 | 7.32 | 131.42 | 0.0608 | 0.1818 | -- | 11,314,930.00 | -21.69 | -- | -22.60 | -- | 99.29 | -- | -356.68 | -- | 66.04 | -- | 0.00 | -- | -49.37 | -- | -192.28 | -- | -- | -- |
| Chiome Bioscience Inc | 682.46m | -1.22bn | 6.86bn | 51.00 | -- | 5.59 | -- | 10.05 | -24.67 | -24.67 | 13.77 | 22.00 | 0.3441 | 4.19 | 6.88 | 13,381,650.00 | -61.51 | -50.50 | -79.81 | -57.38 | 58.41 | 57.53 | -178.77 | -224.74 | 2.90 | -513.93 | 0.2009 | -- | 8.19 | 26.24 | 1.84 | -- | -- | -- |
| NIPPON CHEMIPHAR CO., LTD. | 30.61bn | -241.00m | 6.86bn | 872.00 | -- | 0.31 | 5.74 | 0.2241 | -66.77 | -66.77 | 8,482.42 | 5,194.10 | 0.6063 | 2.09 | 2.65 | 35,106,650.00 | -0.4793 | 1.20 | -0.6777 | 1.74 | 25.09 | 34.53 | -0.7905 | 1.77 | 1.61 | -- | 0.4852 | 38.20 | -2.91 | -2.23 | -51.57 | -21.81 | -13.06 | -12.94 |
| Carna Biosciences, Inc. | 1.63bn | -1.15bn | 7.00bn | 67.00 | -- | 1.80 | -- | 4.30 | -69.84 | -69.84 | 96.78 | 226.16 | 0.3774 | 1.36 | 3.35 | 24,267,000.00 | -26.76 | -14.45 | -29.55 | -16.95 | 89.22 | 90.59 | -70.91 | -35.42 | 10.78 | -312.97 | 0.0451 | -- | 17.24 | 16.59 | 14.57 | -- | -27.69 | -- |
| K Pharma Inc | 1.00bn | 260.33m | 7.28bn | 15.00 | 27.61 | 2.34 | -- | 7.28 | 22.71 | 22.71 | 86.17 | 267.55 | -- | -- | -- | 66,666,670.00 | -- | -- | -- | -- | 91.00 | -- | 26.03 | -- | 18.48 | -- | 0.00 | -- | -- | -- | 166.34 | -- | -- | -- |
| DNA Chip Research Inc | 431.66m | -284.71m | 7.39bn | 36.00 | -- | 14.75 | -- | 17.12 | -45.19 | -45.19 | 68.77 | 74.44 | 0.6728 | 8.52 | 5.31 | 11,990,420.00 | -44.38 | -21.72 | -55.27 | -24.43 | 6.02 | 17.16 | -65.96 | -50.03 | 1.90 | -- | 0.00 | -- | -23.46 | -2.03 | -170.31 | -- | 33.58 | -- |
| Symbio Pharmaceuticals Ltd | 5.59bn | -1.96bn | 7.89bn | 109.00 | -- | 1.01 | -- | 1.41 | -48.74 | -48.74 | 139.70 | 170.89 | 0.6009 | 3.36 | 3.73 | 51,281,720.00 | -21.10 | -19.18 | -24.97 | -23.62 | 78.91 | 65.84 | -35.11 | -24.32 | 8.21 | -- | 0.00 | -- | -44.15 | 7.82 | -266.45 | -- | 42.39 | -- |
| Wakamoto Pharmaceutical Co Ltd | 7.98bn | -177.67m | 7.98bn | 292.00 | -- | 0.6792 | 34.30 | 0.9999 | -5.12 | -5.12 | 229.89 | 337.15 | 0.525 | 2.08 | 2.88 | 27,324,600.00 | -1.17 | -2.58 | -1.34 | -3.00 | 46.98 | 53.08 | -2.23 | -4.33 | 3.45 | -- | 0.0085 | -- | 3.31 | -4.50 | -42.04 | 1.88 | -17.49 | 0.00 |
| CanBas Co Ltd (Parent) | 0.00 | -1.07bn | 8.31bn | 12.00 | -- | 2.64 | -- | -- | -64.96 | -64.96 | 0.00 | 174.81 | 0.00 | -- | -- | 0.00 | -40.62 | -65.86 | -42.95 | -79.11 | -- | -- | -- | -1,094.10 | -- | -- | 0.00 | -- | -- | -- | -45.41 | -- | -- | -- |
| Kohjin Bio Co Ltd | -100.00bn | -100.00bn | 8.61bn | 157.00 | -- | 2.70 | -- | -- | -- | -- | -- | 634.95 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.15 | -- | 0.4102 | -- | 20.16 | -- | 41.20 | -- | -- | -- |
| Tsubota Laboratory Inc | 246.60m | -1.07bn | 9.11bn | 10.00 | -- | 8.65 | -- | 36.92 | -42.31 | -42.31 | 9.94 | 41.17 | 0.1023 | 2.20 | 29.16 | 24,660,200.00 | -44.25 | -- | -64.34 | -- | -182.07 | -- | -432.63 | -- | 1.92 | -417.04 | 0.1046 | -- | 48.96 | -- | -41.18 | -- | -- | -- |
| Stella Pharma Corp | 254.09m | -765.17m | 9.43bn | 46.00 | -- | 3.53 | -- | 37.11 | -25.23 | -25.23 | 8.32 | 85.55 | 0.0637 | 0.0456 | 3.58 | 5,523,718.00 | -19.18 | -- | -20.37 | -- | 82.76 | -- | -301.14 | -- | 11.90 | -1,173.12 | 0.2671 | -- | 128.85 | -- | -1.45 | -- | -- | -- |
| 3-D Matrix Ltd | 3.74bn | -1.06bn | 9.47bn | 108.00 | -- | 15.49 | -- | 2.53 | -14.90 | -14.90 | 54.06 | 7.74 | 0.6653 | 0.4654 | 5.19 | 34,630,130.00 | -18.91 | -57.69 | -23.28 | -77.31 | 64.04 | 40.76 | -28.43 | -205.34 | 2.33 | -- | 0.8717 | -- | 53.63 | 58.87 | -29.09 | -- | -7.69 | -- |
| Linical Co Ltd | 12.52bn | 680.40m | 10.12bn | 759.00 | 13.58 | 1.18 | 8.51 | 0.8083 | 30.12 | 30.12 | 554.28 | 346.38 | 0.7251 | -- | 3.99 | 16,494,230.00 | 3.94 | 4.71 | 6.55 | 7.23 | 33.10 | 31.60 | 5.43 | 5.98 | -- | 17,809.03 | 0.2793 | 45.36 | 8.32 | 6.55 | 27.06 | -4.97 | -33.01 | 4.94 |
Data as of May 02 2024. Currency figures normalised to Wakamoto Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY
2.16%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Nomura Asset Management Co., Ltd.as of 29 Mar 2024 | 287.40k | 0.83% |
| Nikko Asset Management Co., Ltd.as of 05 Apr 2024 | 136.90k | 0.39% |
| Daiwa Asset Management Co. Ltd.as of 29 Mar 2024 | 131.90k | 0.38% |
| Mitsubishi UFJ Asset Management Co., Ltd.as of 05 Apr 2024 | 61.00k | 0.18% |
| BlackRock Japan Co. Ltd.as of 04 Apr 2024 | 60.30k | 0.17% |
| Sumitomo Mitsui Trust Asset Management Co., Ltd.as of 20 Apr 2023 | 24.30k | 0.07% |
| Dimensional Fund Advisors LPas of 31 Jan 2024 | 19.60k | 0.06% |
| Asset Management One Co., Ltd.as of 04 Apr 2024 | 15.20k | 0.04% |
| Norinchukin Zenkyoren Asset Management Co., Ltd.as of 04 Apr 2024 | 9.90k | 0.03% |
| Amundi Asset Management SA (Investment Management)as of 03 Apr 2024 | 6.88k | 0.02% |
More ▼
Data from 31 Dec 2023 - 01 May 2024Source: FactSet Research Systems Inc.
